Endocrine Abstracts

Radioiodine therapy (RAI): which is the cornerstone of the treatment of distant metastasis from differentiated thyroid cancers (DTC), is based on the expression of the iodine transporter NIS. The majority of DTC are papillary with BRAFV600E mutation in 45% to 60% of cases. This mutation is associated with RAI refractory DTC with a low NIS expression and a low differentiation score. The absence of RAI uptake is a major challenge for the treatment of patients. A promi...